Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy

Open Access

Peer-reviewed

Research Article

Prasun J. Mishra ,

* E-mail: mishra.prasun@gene.com (PJM); gmerlino@helix.nih.gov (GM)

Affiliations Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, California, United States of America, Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Pravin J. Mishra,

Affiliation Precision Genomics, Intermountain Healthcare, Dixie Regional Medical Center, St. George, Utah, United States of America
⨯
Glenn Merlino

* E-mail: mishra.prasun@gene.com (PJM); gmerlino@helix.nih.gov (GM)

Affiliation Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
⨯

Reader Comments (0)

Melanoma
Is the Subject Area "Melanoma" applicable to this article?

Thanks for your feedback.
Melanocytes
Is the Subject Area "Melanocytes" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Skin tumors
Is the Subject Area "Skin tumors" applicable to this article?

Thanks for your feedback.
Transfection
Is the Subject Area "Transfection" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cutaneous melanoma
Is the Subject Area "Cutaneous melanoma" applicable to this article?

Thanks for your feedback.
MicroRNAs
Is the Subject Area "MicroRNAs" applicable to this article?

Thanks for your feedback.